Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Biosimilars: SOP for Creation of Master Cell Bank (MCB) – V 2.0

Posted on By


Biosimilars: SOP for Creation of Master Cell Bank (MCB) – V 2.0


Standard Operating Procedure for Creation of Master Cell Bank (MCB) in Biosimilars

Department Biosimilars
SOP No. SOP/BS/024/2025
Supersedes SOP/BS/024/2022
Page No. Page 1 of 14
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To outline the procedure for the preparation, qualification, documentation, and storage of Master Cell Banks (MCBs) derived from biosimilar-producing cell lines intended for GMP manufacturing.

2. Scope

This SOP applies to the Cell Line Development and Quality Control departments involved in the generation, testing, and archival of MCBs under GMP conditions.

3. Responsibilities

  • CLD Scientist: Prepares and freezes MCB vials under controlled aseptic conditions.
  • QC Microbiologist: Conducts sterility, mycoplasma, identity, and viability testing.
  • QA Officer: Ensures all MCB-related activities are documented, reviewed, and approved as per GMP standards.
See also  Biosimilars: SOP for Western Blotting for Protein Expression - V 2.0

4. Accountability

The Head of Biosimilars is accountable for ensuring that the MCB is prepared, characterized, and stored in compliance with regulatory expectations and internal quality systems.

5. Procedure

5.1 Pre-Freezing Preparation

  1. Use a genetically and phenotypically stable cell clone that has passed clone stability studies (refer SOP/BS/023/2025).
  2. Thaw and expand the selected clone in a progressive scale-up from T-flasks → spinner flasks → production bioreactor (if applicable).
  3. Monitor viable cell density (>90% viability) before harvest.

5.2 Cryopreservation Media

  1. Prepare freezing medium: 90% basal media + 10% DMSO under sterile conditions.
  2. Filter sterilize the medium using 0.22 µm filters.

5.3 MCB Aliquoting and Labeling

  1. Resuspend cells at 5 × 106 cells/mL in freezing media.
  2. Dispense 1 mL into pre-labeled sterile cryovials (minimum 100 vials recommended).
  3. Labels must include:
    • Cell Line ID
    • MCB Lot Number
    • Date of Freezing
    • Passage Number
    • Technician Initials
See also  Biosimilars: SOP for Limiting Dilution Cloning - V 2.0

5.4 Controlled Freezing

  1. Place vials into a programmable rate freezer: -1°C/min until -80°C.
  2. Transfer to liquid nitrogen (-196°C) storage tank after 12–24 hours.

5.5 Quality Control Testing

  1. Send representative vials for:
    • Cell viability
    • Sterility (as per USP <71>)
    • Mycoplasma (culture and PCR-based)
    • Cell line identity (STR profiling)
    • Adventitious virus testing (where required)
  2. Record all results in MCB QC Log (Annexure-1).

5.6 Documentation and Archival

  1. Maintain freezing records and storage inventory in MCB Inventory Log (Annexure-2).
  2. Prepare MCB Certificate of Analysis upon completion of QC testing.

6. Abbreviations

  • MCB: Master Cell Bank
  • DMSO: Dimethyl Sulfoxide
  • STR: Short Tandem Repeat
  • QC: Quality Control

7. Documents

  1. MCB QC Log (Annexure-1)
  2. MCB Inventory Log (Annexure-2)

8. References

  • ICH Q5D – Derivation and Characterization of Cell Substrates
  • WHO Technical Report Series No. 978 – Cell Substrate Guidelines
  • CDSCO Biosimilar Guidelines (India)

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: MCB QC Log

Test Method Result Acceptance Criteria Remarks
Viability Trypan Blue 94% ≥ 85% Pass
Sterility USP <71> Negative No growth Pass
Mycoplasma PCR + Culture Negative Absent Pass
STR Profile Capillary Electrophoresis Matched 100% match Pass

Annexure-2: MCB Inventory Log

Vial No. Cell Line ID MCB Lot No. Freezing Date Location (Tank/Rack/Box) Operator
MCB001 CL-BS-024 MCB-BS-24A 03/05/2025 T1/R2/B4 Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
04/05/2025 2.0 Updated storage practices and included STR and virus testing Regulatory update and audit recommendation
See also  Biosimilars: SOP for Vector Design and Cloning - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Tablets: SOP for Ensuring Tamper-Evident Sealing in Packaging – V 2.0
Next Post: BA-BE Studies: SOP for IMP Destruction or Return Process – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version